Found: 45
Select item for more details and to access through your institution.
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
- Published in:
- Cardiovascular Toxicology, 2007, v. 7, n. 2, p. 67, doi. 10.1007/s12012-007-0013-5
- By:
- Publication type:
- Article
Pharmacology and Clinical Toxicity of 4′-Iodo-4′-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1990, v. 82, n. 6, p. 469
- By:
- Publication type:
- Article
Role of Daunosamine and Hydroxyacetyl Side Chain in Reaction With Iron and Lipid Peroxidation by Anthracyclines2.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1988, v. 80, n. 14, p. 1104
- By:
- Publication type:
- Article
Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr<sup>701</sup> phosphorylation.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
- Published in:
- BJU International, 2009, v. 104, n. 3, p. 340, doi. 10.1111/j.1464-410X.2009.08453.x
- By:
- Publication type:
- Article
Monoclonal antibodies against doxorubicin.
- Published in:
- International Journal of Cancer, 1988, v. 42, n. 5, p. 798, doi. 10.1002/ijc.2910420528
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1188, doi. 10.1007/s10637-014-0119-0
- By:
- Publication type:
- Article
Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0123194
- By:
- Publication type:
- Article
Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0086511
- By:
- Publication type:
- Article
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00439-5
- By:
- Publication type:
- Article
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-021-00377-8
- By:
- Publication type:
- Article
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 5051, doi. 10.3390/cancers14205051
- By:
- Publication type:
- Article
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 296, doi. 10.3390/cancers11030296
- By:
- Publication type:
- Article
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 12, p. 2355, doi. 10.1002/1878-0261.13141
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1236, doi. 10.1007/s10637-013-9942-y
- By:
- Publication type:
- Article
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 155, n. 1, p. 127, doi. 10.1007/s10549-015-3656-0
- By:
- Publication type:
- Article
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 132, n. 3, p. 843, doi. 10.1007/s10549-011-1660-6
- By:
- Publication type:
- Article
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 125, n. 2, p. 447, doi. 10.1007/s10549-010-1260-x
- By:
- Publication type:
- Article
Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
- Published in:
- Breast Cancer Research & Treatment, 2009, v. 117, n. 3, p. 599, doi. 10.1007/s10549-009-0402-5
- By:
- Publication type:
- Article
Development and validation of a gene expression-based Breast Cancer Purity Score.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00730-7
- By:
- Publication type:
- Article
Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 11, p. 12071, doi. 10.1002/cam4.5893
- By:
- Publication type:
- Article
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918762094
- By:
- Publication type:
- Article
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 3, p. 1, doi. 10.1186/bcr3661
- By:
- Publication type:
- Article
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Report on the International Colloquium on Cardio-Oncology (Rome, 12-14 March 2014).
- Published in:
- Ecancermedicalscience, 2014, v. 8, n. 413-446, p. 1, doi. 10.3332/ecancer.2014.433
- By:
- Publication type:
- Article
Hallmarks of triple negative breast cancer emerging at last?
- Published in:
- Cell Research, 2014, v. 24, n. 8, p. 904, doi. 10.1038/cr.2014.61
- By:
- Publication type:
- Article
Breast cancer: diagnostic and therapeutic options.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2004, v. 31, p. S1, doi. 10.1007/s00259-004-1521-1
- By:
- Publication type:
- Article
The choice of the correct imaging modality in breast cancer management.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2004, v. 31, p. S179, doi. 10.1007/s00259-004-1541-x
- By:
- Publication type:
- Article
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr<sup>701</sup> phosphorylation.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-73835-1
- By:
- Publication type:
- Article
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 12, p. 2025, doi. 10.1038/s41416-023-02477-7
- By:
- Publication type:
- Article
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level(Iressa is a trademark of the AstraZeneca group of companies.)
- Published in:
- Journal of Cellular Physiology, 2004, v. 198, n. 2, p. 259, doi. 10.1002/jcp.10411
- By:
- Publication type:
- Article
Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour DNA Mutations.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 8, p. 769, doi. 10.3390/cells8080769
- By:
- Publication type:
- Article
Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
- Published in:
- Journal of Neuro-Oncology, 2008, v. 86, n. 1, p. 89, doi. 10.1007/s11060-007-9438-8
- By:
- Publication type:
- Article
The Future of Targeted Therapy: Combining Novel Agents.
- Published in:
- Oncology, 2002, v. 63, p. 47, doi. 10.1159/000066197
- By:
- Publication type:
- Article
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00467-1
- By:
- Publication type:
- Article
Triple-Negative Breast Cancer: An Unmet Medical Need.
- Published in:
- Oncologist, 2011, v. 16, p. 1, doi. 10.1634/theoncologist.2011-S1-01
- By:
- Publication type:
- Article
Triple-Negative Breast Cancer: An Unmet Medical Need.
- Published in:
- Oncologist, 2011, v. 16, p. 1, doi. 10.1634/theoncologist.2011-S1-01
- By:
- Publication type:
- Article
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
- Published in:
- PLoS ONE, 2018, v. 13, n. 7, p. 1, doi. 10.1371/journal.pone.0201425
- By:
- Publication type:
- Article
HER2-Directed T-Cell Receptor–Mimicking Antibody: A “Me Too” or an Example of Novel Antitumor Aggressive Mimicry?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 3, p. 161, doi. 10.1093/jnci/djs636
- By:
- Publication type:
- Article